FDA hormone therapy warning changes: what women need to know

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published November 19, 2025 • Updated May 1, 2026

The FDA hormone therapy warning changes matter because women have been harmed by overcorrection. For years, too many patients were told that hormone replacement therapy was dangerous, full stop. No nuance. No timing. No route. No discussion of why a 52-year-old with severe hot flashes is not the same clinical situation as a 72-year-old starting therapy for the first time.

Let me be clear: the old conversation around HRT was broken. It scared symptomatic women away from effective treatment, while also failing to teach them what safe prescribing actually requires.

Here is what I see in my practice. Women come in exhausted from hot flashes, night sweats, insomnia, brain fog, joint pain, and mood disruption. They were told, “Hormones cause cancer,” and then handed an antidepressant, a sleep medication, and another lecture about exercise. That is not informed consent. That is fear-based avoidance.

What Changed With FDA Hormone Therapy Warnings?

The FDA approved labeling changes for menopausal hormone therapy products after reviewing current evidence and expert advisory input. The agency described changes that include removing the boxed warning from many menopausal hormone therapy products and updating language so the benefit-risk conversation is clearer for women using these products for menopause symptoms.

The FDA also emphasized that hormone therapy should be individualized and used with appropriate evaluation. That is the part I do not want anyone to skip. Removing misleading blanket warnings is not the same as removing clinical judgment.

The old label language trained a generation of clinicians to think about menopause hormone therapy through a single fear lens. The new direction forces a more accurate conversation: who is the woman, how old is she, how long has it been since menopause, what symptoms does she have, what route is being considered, does she have a uterus, and what are her personal risks?

Why the Old Warning Was Too Blunt

The older warnings were heavily shaped by early interpretation of the Women's Health Initiative. The WHI was important, but the public takeaway became distorted. Women and clinicians heard one message: HRT is dangerous. The details were buried.

The WHI included older postmenopausal women on specific hormone formulations. It did not answer every question about transdermal estradiol, micronized progesterone, younger symptomatic women, early menopause, surgical menopause, or route-specific risk. Yet the fear got applied broadly.

The North American Menopause Society stated in its 2022 position statement in Menopause that for women younger than 60 years or within 10 years of menopause onset who have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss. That is not a fringe statement. That is mainstream menopause medicine.

What Did Not Change: HRT Still Requires Screening

The FDA label change does not mean every woman should use hormones. It means the decision should be specific. I still screen for breast cancer history, blood clot history, stroke or heart attack history, unexplained vaginal bleeding, liver disease, migraine pattern, blood pressure, smoking status, family history, and time since menopause.

I also ask whether the woman has a uterus. If she does and she uses systemic estrogen, she generally needs adequate progesterone or another endometrial-protective strategy. Estrogen without uterine protection can stimulate the lining of the uterus and raise endometrial cancer risk. That did not change because a warning label changed.

This is where telehealth script mills get it wrong. They frame hormones as access. I frame hormones as management. The medication is only one part of the care.

Route Matters More Than Most Women Are Told

Oral estrogen and transdermal estradiol are not identical. Oral estrogen goes through the liver first. Transdermal estradiol, including an estradiol patch, bypasses first-pass liver metabolism. That route difference affects how I counsel women about clot risk, triglycerides, migraine, blood pressure, and metabolic context.

ACOG's Committee Opinion on route of estrogen administration and venous thromboembolism risk notes that orally administered estrogen may exert a prothrombotic effect, while transdermal estrogen has little or no effect on prothrombotic substances. A 2010 review by Canonico and colleagues in Current Opinion in Hematology reached the same practical conclusion: transdermal estrogen appears to have less clotting impact than oral estrogen in observational evidence.

That does not make the patch risk-free. It makes the route part of the decision. If your clinician says “HRT” without discussing formulation and route, the conversation is incomplete.

Route also matters because women arrive with different histories. A woman with migraine with aura, high triglycerides, hypertension, insulin resistance, or a family history of clotting deserves a more careful conversation than “estrogen is estrogen.” A woman who only needs vaginal symptom treatment may not need systemic therapy at all. A woman in early surgical menopause may need a completely different risk-benefit discussion than a woman starting systemic therapy decades after menopause.

This is why the FDA hormone therapy warning changes are helpful but not sufficient by themselves. Labels guide the conversation. They do not replace the clinician's job.

The Warning Change Is Also a Trust Issue

Women lost trust because they were told two opposite stories. First, hormones were treated like a fountain of youth. Then hormones were treated like poison. Neither extreme was good medicine.

What women need now is not hype. They need a mature conversation. Hormone therapy can be the right decision for many symptomatic women. It can also be the wrong decision for others. The skill is knowing the difference.

The American College of Obstetricians and Gynecologists supported clearer labeling because better information can improve access to evidence-based hormone therapy. I agree with that direction. But access without follow-up is still not enough.

Women remember being dismissed. They remember asking about HRT and being told, “We do not do that anymore,” as if menopause medicine had ended in 2002. They remember being offered sleeping pills for night sweats, antidepressants for estrogen-withdrawal mood changes, and weight-loss lectures for metabolic shifts that started with perimenopause.

That history matters. When medicine overcorrects, patients pay for it in years of symptoms, missed work, fractured sleep, sexual pain, bone loss, and loss of trust. The new labeling does not erase that damage, but it gives clinicians a chance to practice with more accuracy.

What I Tell Patients Now

If you are in perimenopause or menopause and your symptoms are disrupting sleep, work, relationships, or metabolic health, you deserve a real HRT discussion. You do not deserve dismissal because your clinician is uncomfortable with updated menopause data.

I tell women to ask these questions:

• Am I a candidate? Based on age, timing, symptoms, history, and contraindications.
• What route are we using? Oral, patch, gel, spray, ring, or local vaginal therapy are not the same.
• Do I need progesterone? Uterus status changes the safety plan.
• What are we measuring? Symptoms, bleeding, blood pressure, breast screening, metabolic markers, and response.
• When do we reassess? A prescription without a follow-up plan is not a protocol.

This is what nobody tells you: the safest hormone plan is not the lowest-effort plan. It is the plan that matches your biology and gets adjusted when your body gives us new information.

What Still Gets Missed in HRT Counseling

The biggest miss is pretending that the decision is only “yes hormones” or “no hormones.” Real counseling includes route, dose, duration, symptom target, uterus status, breast screening, bleeding plan, metabolic context, and what we will do if the first version is not right.

I also want women to understand the difference between systemic and local therapy. Local vaginal estrogen for genitourinary symptoms is not the same conversation as systemic estrogen for hot flashes, sleep disruption, or bone protection. The risk discussion changes with dose and route.

Another miss is follow-up. If a woman starts HRT and has bleeding, breast tenderness, headaches, mood changes, persistent insomnia, or no symptom relief, the plan should be reassessed. A refill is not a review. A portal message saying “give it more time” is not a protocol.

Good HRT care is active management. It is not fear. It is not hype. It is medicine.

How Gaya Handles Hormone Therapy

Inside Hormonal Agency™, we do not sell women a generic hormone script and call it optimization. We review symptoms, timeline, uterus status, bleeding history, risk factors, prior labs, family history, breast screening status, metabolic context, and what has already failed.

For some women, the right answer is transdermal estradiol plus progesterone. For others, it is local vaginal estrogen, nonhormonal therapy, thyroid evaluation, sleep workup, or medical weight-loss support. For women whose stubborn weight gain and hormones overlap, we coordinate with Weight Loss Concierge when appropriate.

The point is not to put every woman on HRT. The point is to stop denying women access to evidence-based care because the system never updated its script.

You Deserve Better Than Blanket Fear

The FDA hormone therapy warning changes are a correction, not a free-for-all. They acknowledge that women need clearer benefit-risk language and that the old fear-based labeling did not serve the patient in front of us.

If you have been suffering because someone told you hormones were automatically dangerous, I want you to hear this: you are not asking for vanity medicine. You are asking for menopause care. That care should be evidence-based, specific, and supervised.

You have not failed. Your plan did.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in medical weight loss, hormone optimization, and longevity medicine for women in midlife and beyond.